International Stem Cell Corporation (OTCBB: ISCO), www.internationalstemcell.com, announced today that it has expanded its market awareness program by joining www.StockProfile.com, a customized web-based platform showcasing emerging growth stocks.
StockProfile.com provides the investing public with a free unique information portal for investors who like to conduct their own research and make their own investment decisions. The platform allows users to review and investigate dynamic publicly traded companies in a user-friendly environment.
International Stem Cell Corporation is pleased to provide corporate information to StockProfile.com's independent investors seeking information about new growth companies. The profile is listed at www.StockProfile.com and can be viewed by searching under the stock symbol ISCO.
Brian Lundstrom, President of ISCO said, "This is another important step ISCO is taking to ensure that its shareholders and the investment community have continued access to information about our latest announcements, products and services. We're pleased to add StockProfile.com to our market awareness program and we will continue to explore additional market outreach strategies."
ABOUT INTERNATIONAL STEM CELL CORPORATION (ISCO.OB):
International Stem Cell Corporation is a California-based biotechnology company focused on therapeutic and research products. ISCO's core technology, parthenogenesis, results in creation of pluripotent human stem cells from unfertilized oocytes (eggs). ISCO scientists have created the first parthenogenic, homozygous stem cell line that can be a source of therapeutic cells with minimal immune rejection after transplantation into hundreds of millions of individuals of differing sexes, ages and racial groups. This offers the potential to create the first true stem cell bank, UniStemCell™, while avoiding the ethical issue of using fertilized eggs. ISCO also produces and markets specialized cells and growth media for therapeutic research worldwide through its subsidiary Lifeline Cell Technology. More information is available at ISCO's website, www.internationalstemcell.com
To subscribe to receive ongoing corporate communications please click on the following link: http://www.b2i.us/irpass.asp?BzID=1468&to=ea&s=0.
Statements pertaining to anticipated future financial and/or operating results, future growth in research, technology, clinical development and potential joint venture and other opportunities for the company and its subsidiary, along with other statements about the future expectations, beliefs, goals, plans, or prospects expressed by management constitute forward-looking statements. Any statements that are not historical fact (including, but not limited to statements that contain words such as "will," "believes," "plans," "anticipates," "expects," "estimates,") should also be considered to be forward-looking statements. Forward-looking statements involve risks and uncertainties, including, without limitation, risks inherent in the development and/or commercialization of potential products, uncertainty in the results of clinical trials or regulatory approvals, need and ability to obtain future capital, application of capital resources among competing uses, and maintenance of intellectual property rights. Actual results may differ materially from the results anticipated in these forward-looking statements and as such should be evaluated together with the many uncertainties that affect the company's business, particularly those mentioned in the cautionary statements found in the company's Securities and Exchange Commission filings. The company disclaims any intent or obligation to update these forward-looking statements.
Key Words: Stem Cells, Biotechnology, Parthenogenesis
International Stem Cell Corporation
Kenneth C. Aldrich, Chairman
Brian Lundstrom, President